OR WAIT null SECS
January 28, 2022
IonSense’s DART-MS technology offers rapid drug analysis without the need for sample preparation.
Texcell North America’s new lab facility in Frederick, Md., will expand the CRO’s capabilities in R&D cell culture, viral clearance studies, and viral safety testing.
Refeyn’s SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterization
Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.
PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.
BenchSci, a specialist in machine learning applications for novel medicine development, has completed a Series C financing round.
Scottish biotech engineering company, uFraction8, has successfully secured more than £2.5 million ($3.3 million) in new investment.
NICE has updated its Technology Appraisal Guidance TA599 for AstraZeneca’s Lokelma.
Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.
January 27, 2022
Merger with Phlexglobal expands provider’s technological capabilities.